The influence of Sr doses on the in vitro biocompatibility and in vivo degradability of single-phase Sr-incorporated HAP cement.
ABSTRACT In previous studies, we developed a new type of Sr-incorporated hydroxyapatite cement (Sr-HAC), which was shown to have many excellent physiochemical properties, by an ionic cement route (Guo et al., Biomaterials 2005;26:4073-4083). As a further study, the main aims of this article were to examine the Sr-HAC's in vitro biocompatibility, including acute toxicity, hemolytic reaction, pyrogen reaction, and cytoxicity, to evaluate its in vivo degradability during intramuscular and femur implantation, and also to investigate the influence of Sr doses on these properties. The in vitro results show that all of the Sr-HAC samples exhibit satisfactory biocompatibility, and the Sr/(Sr+Ca) molar ratio has an important effect on these properties. For example, the Sr-HAC with a Sr/(Sr+Ca) molar ratio of 5% (5% Sr-HAC) has higher biocompatibility than both the one with a Sr/(Sr+Ca) molar ratio of 10% (10% Sr-HAC) and the Sr-free one. The in vivo results of both the rabbit intramuscular and femur implantation experiments show that the Sr-HAC samples exhibit a much faster degradation rate than the Sr-free one, and that this also depends on the Sr/(Sr+Ca) molar ratio. Specifically, the mean degradation rate of the 10% Sr-HAC increases by an amplitude of 73.9 wt % compared with that of the Sr-free HAC. In addition, the optical transmission photographs show that the Sr doses play an important role on the interface between the implants and the new bone. The energy dispersion X-ray spectrum analysis indicates that there exists a gradient distribution of Sr element in the tight and bioactive interface between the implants and new bone, indicating that the Sr element takes a share in the mineralization of the new bone together with Ca element.
- SourceAvailable from: link.springer.com[Show abstract] [Hide abstract]
ABSTRACT: Calcium phosphate cements are used frequently in orthopedic and dental surgeries. Strontium-containing drugs serve as systemic osteoblast-activating medication in various clinical settings promoting mechanical stability of the osteoporotic bone. Strontium-containing calcium phosphate cement (SPC) and calcium phosphate cement (CPC) were compared regarding their local and systemic effects on bone tissue in a standard animal model for osteoporotic bone. A bone defect was created in the distal femoral metaphysis of 60 ovariectomized Sprague-Dawley rats. CPC and SPC were used to fill the defects in 30 rats in each group. Local effects were assessed by histomorphometry at the implant site. Systemic effects were assessed by bone mineral density (BMD) measurements at the contralateral femur and the spine. Faster osseointegration and more new bone formation were found for SPC as compared to CPC implant sites. SPC implants exhibited more cracks than CPC implants, allowing more bone formation within the implant. Contralateral femur BMD and spine BMD did not differ significantly between the groups. The addition of strontium to calcium phosphate stimulates bone formation in and around the implant. Systemic release of strontium from the SPC implants did not lead to sufficiently high serum strontium levels to induce significant systemic effects on bone mass in this rat model.Journal of Orthopaedic Surgery and Research 01/2013; 8:16. · 1.01 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: Strontium-substituted calcium phosphate coatings are synthesized by pulsed electrodeposition on titanium alloy (Ti6Al4V) substrates. Experimental conditions of the process are optimized in order to obtain a coating with a 5% atomic substitution of calcium by strontium which corresponds to the best observations on the osteoblast cells activity and on the osteoclast cells proliferation. The physical and chemical characterizations of the obtained coating are carried out by scanning electron microscopy associated to energy dispersive X-ray spectroscopy (EDXS) for X-ray microanalysis and the structural characterization of the coating is carried out by X-ray diffraction. The in vitro dissolution/precipitation properties of the coated substrates are investigated by immersion into Dulbecco's Modified Eagle Medium (DMEM) from 1h to 14days. The calcium, phosphorus and strontium concentrations variations in the biological liquid are assessed by Induced Coupled Plasma - Atomic Emission Spectroscopy for each immersion time. The results show that under specific experimental conditions, the electrodeposition process is suitable to synthesize strontium-substituted calcium phosphate coatings. Moreover, the addition of hydrogen peroxide (H2O2) into the electrolytic solution used in the process allows us to observe a control of the strontium release during the immersion of the prosthetic materials into DMEM.Materials science & engineering. C, Materials for biological applications. 10/2013; 33(7):4260-5.
- [Show abstract] [Hide abstract]
ABSTRACT: In the present study, the in vitro effects of novel strontium-modified calcium phosphate bone cements (SrCPC), prepared using two different approaches on human bone-marrow derived mesenchymal stem cells (hMSC) were evaluated. Strontium ions, known to stimulate bone formation and therefore already used in systemic osteoporosis therapy, were incorporated into a hydroxyapatite forming calcium phosphate bone cement via two simple approaches: Incorporation of strontium carbonate crystals or substitution of Ca2+- by Sr2+-ions during cement setting. All modified cements released 0.03-0.07 mM Sr2+ under in vitro conditions, concentrations that were shown not to impair the proliferation or osteogenic differentiation of hMSC. Furthermore, strontium-modification led to a reduced medium acidification and Ca2+-depletion in comparison to the standard calcium phosphate cement. In indirect and direct cell culture experiments with the novel SrCPC significantly enhanced cell proliferation and differentiation was observed. In conclusion, the SrCPC described here could be beneficial for the local treatment of defects especially in the osteoporotic bone.Acta Biomaterialia 07/2013; · 5.09 Impact Factor